Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2011

01.03.2011 | Original Article

Computer-Assisted Analysis of Abrasive Transepithelial Brush Biopsies Increases the Effectiveness of Esophageal Screening: A Multicenter Prospective Clinical Trial by the EndoCDx Collaborative Group

verfasst von: J. F. Johanson, J. Frakes, D. Eisen, EndoCDx Collaborative Group

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The sensitivity of screening for Barrett’s esophagus (BE) and esophageal dysplasia (ED) is hampered by the limited amount of tissue that can be sampled by forceps biopsy (FB).

Aim

The aim of this study was to evaluate computer assisted analysis of an abrasive, transepithelail brush biopsy as an adjunct to FB to increase detection of BE and ED.

Methods

This was a multicenter prospective trial of patients being screened for BE and ED. Each patient had two brush biopsies (BB) and then random four-quadrant FB every 1–2 cm of the esophagus. All BB were examined with computer assistance by pathologists at CDx Laboratories (Suffern, NY), and all FB were examined by the investigators’ local pathologists.

Results

Of 1,266 patients enrolled, 363 were diagnosed with BE by FB alone and 146 additional cases of BE were identified by adding BB. The addition of BB to FB increased the overall detection of BE by 39.8% (95% CI 32–48%). This added detection of BE in 11.5% of all patients tested with the BB (146/1266) resulted in a number of patients needed to test (NNT) to obtain each additional positive finding of Barrett’s esophagus of 8.7. Among a subset of 848 patients with gastroesophageal reflux disease and no prior history of BE, the addition of BB to FB identified an additional 105 patients with BE increasing the overall detection of BE by 70.5% (95% CI 54–90%). Dysplasia was diagnosed in 16 patients by FB alone, with an additional 14 cases detected by adding BB. The addition of BB to FB thus increased the detection of ED by 87.5%.

Conclusion

These results suggest that adjunctive computer-assisted analysis of an abrasive brush biopsy has the potential to substantially improve the detection of Barrett’s esophagus and dysplasia in screening populations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mashimo H, Wagh MS, Goyal RK. Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol. 2005;39:S33–S41.CrossRefPubMed Mashimo H, Wagh MS, Goyal RK. Surveillance and screening for Barrett esophagus and adenocarcinoma. J Clin Gastroenterol. 2005;39:S33–S41.CrossRefPubMed
2.
Zurück zum Zitat Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54:i1–i5.CrossRefPubMed Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54:i1–i5.CrossRefPubMed
3.
Zurück zum Zitat Cossentino MJ, Wong RK. Barrett’s esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:128–135.PubMed Cossentino MJ, Wong RK. Barrett’s esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis. 2003;14:128–135.PubMed
5.
Zurück zum Zitat Shaheen NJ. Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128:1554–1566.CrossRefPubMed Shaheen NJ. Advances in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128:1554–1566.CrossRefPubMed
6.
Zurück zum Zitat Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.CrossRefPubMed Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist. 2005;10:590–601.CrossRefPubMed
7.
Zurück zum Zitat Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett’s esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am. 2005;89:293–312.CrossRefPubMed Sampliner RE. Epidemiology, pathophysiology, and treatment of Barrett’s esophagus: reducing mortality from esophageal adenocarcinoma. Med Clin North Am. 2005;89:293–312.CrossRefPubMed
8.
Zurück zum Zitat Olliver JR, et al. Risk factors, DNA damage, and disease progression in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:620–625.CrossRefPubMed Olliver JR, et al. Risk factors, DNA damage, and disease progression in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:620–625.CrossRefPubMed
9.
Zurück zum Zitat Kyrgidis A, et al. New molecular concepts of Barrett’s esophagus: clinical implications and biomarkers. J Surg Res. 2005;125:189–212.CrossRefPubMed Kyrgidis A, et al. New molecular concepts of Barrett’s esophagus: clinical implications and biomarkers. J Surg Res. 2005;125:189–212.CrossRefPubMed
10.
Zurück zum Zitat Reid BJ, et al. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102:1212–1219.PubMed Reid BJ, et al. Flow-cytometric and histological progression to malignancy in Barrett’s esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology. 1992;102:1212–1219.PubMed
11.
Zurück zum Zitat Waye JD. Upper gastrointestinal endoscopy. Mt Sinai J Med. 1995;62:50–59.PubMed Waye JD. Upper gastrointestinal endoscopy. Mt Sinai J Med. 1995;62:50–59.PubMed
12.
Zurück zum Zitat Sharma P. Review article: emerging techniques for screening and surveillance in Barrett’s oesophagus. Aliment Pharmacol Ther. 2004;20:63–70; discussion 95–96.CrossRefPubMed Sharma P. Review article: emerging techniques for screening and surveillance in Barrett’s oesophagus. Aliment Pharmacol Ther. 2004;20:63–70; discussion 95–96.CrossRefPubMed
13.
14.
Zurück zum Zitat Falk GW, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176.CrossRefPubMed Falk GW, et al. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 1999;49:170–176.CrossRefPubMed
15.
Zurück zum Zitat Bergman JJ, Tytgat GN. New developments in the endoscopic surveillance of Barrett’s oesophagus. Gut. 2005;54:i38–i42.CrossRefPubMed Bergman JJ, Tytgat GN. New developments in the endoscopic surveillance of Barrett’s oesophagus. Gut. 2005;54:i38–i42.CrossRefPubMed
16.
Zurück zum Zitat Bergman JJ. Diagnosis and therapy of early neoplasia in Barrett’s esophagus. Curr Opin Gastroenterol. 2005;21:466–471.PubMed Bergman JJ. Diagnosis and therapy of early neoplasia in Barrett’s esophagus. Curr Opin Gastroenterol. 2005;21:466–471.PubMed
18.
Zurück zum Zitat Kara MA, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37:929–936.CrossRefPubMed Kara MA, et al. High-resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett’s esophagus: a prospective randomized crossover study. Endoscopy. 2005;37:929–936.CrossRefPubMed
19.
Zurück zum Zitat Egger K, et al. Biopsy surveillance is still necessary in patients with Barrett’s oesophagus despite new endoscopic imaging techniques. Gut. 2003;52:18–23.CrossRefPubMed Egger K, et al. Biopsy surveillance is still necessary in patients with Barrett’s oesophagus despite new endoscopic imaging techniques. Gut. 2003;52:18–23.CrossRefPubMed
20.
Zurück zum Zitat Boyce HW. Barrett esophagus: endoscopic findings and what to biopsy. J Clin Gastroenterol. 2003;36:S6–S18; discussion S26–S28.CrossRefPubMed Boyce HW. Barrett esophagus: endoscopic findings and what to biopsy. J Clin Gastroenterol. 2003;36:S6–S18; discussion S26–S28.CrossRefPubMed
21.
Zurück zum Zitat Wong Kee Song LM. Optical spectroscopy for the detection of dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2005;3:S2–S7.CrossRefPubMed Wong Kee Song LM. Optical spectroscopy for the detection of dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol. 2005;3:S2–S7.CrossRefPubMed
22.
Zurück zum Zitat Sciubba JJ. Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc. 1999;130:1445–1457.PubMed Sciubba JJ. Improving detection of precancerous and cancerous oral lesions. Computer-assisted analysis of the oral brush biopsy. U.S. Collaborative OralCDx Study Group. J Am Dent Assoc. 1999;130:1445–1457.PubMed
23.
Zurück zum Zitat Scheifele C, et al. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncol. 2004;40:824–828.CrossRefPubMed Scheifele C, et al. The sensitivity and specificity of the OralCDx technique: evaluation of 103 cases. Oral Oncol. 2004;40:824–828.CrossRefPubMed
Metadaten
Titel
Computer-Assisted Analysis of Abrasive Transepithelial Brush Biopsies Increases the Effectiveness of Esophageal Screening: A Multicenter Prospective Clinical Trial by the EndoCDx Collaborative Group
verfasst von
J. F. Johanson
J. Frakes
D. Eisen
EndoCDx Collaborative Group
Publikationsdatum
01.03.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1497-6

Weitere Artikel der Ausgabe 3/2011

Digestive Diseases and Sciences 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.